Therapeutisch relevante prädiktive Biomarker beim Adenokarzinom des Ösophagus

Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

Warneke VS et al (2013) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 24(3):725–733

Tominaga N et al (2016) Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer 19(2):553–560

Lordick F et al (2017) HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol 143(5):835–841

Shitara K et al (2020) Trastuzumab Deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382(25):2419–2430

Freeman GJ et al (2000) Engagement of the PD‑1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034

Huang RSP et al (2021) A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Mod Pathol 34(2):252–263

Janjigian YY et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27–40

Chung HC et al (2021) First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 17(5):491–501

Chao J et al (2021) Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol 2021 Jun 1;7(6):895–902. https://doi.org/10.1001/jamaoncol.2021.0275

Falkenback D et al (2005) Defective mismatch-repair as a minor tumorigenic pathway in Barrett esophagus-associated adenocarcinoma. Cancer Genet Cytogenet 157(1):82–86

Funkhouser WK Jr. et al (2012) Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 14(2):91–103

Gleeson CM et al (1996) Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett’s-associated esophageal adenocarcinoma. Cancer Res 56(2):259–263

Muzeau F et al (1997) Infrequent microsatellite instability in oesophageal cancers. Br J Cancer 75(9):1336–1339

Le DT et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD‑1 blockade. Science 357(6349):409–413

Marabelle A et al (2020) Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1–10

Smyth EC et al (2017) Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol 3(9):1197–1203

Sahin U et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14(23):7624–7634

Singh P, Toom S, Huang Y (2017) Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 10(1):105

Sahin U et al (2018) A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer 100:17–26

Moentenich V et al (2020) Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. Oncol Lett 19(6):3665–3670

Catenacci DV et al (2019) Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT phase III study design. Future Oncol 15(18):2073–2082

Han N et al (2015) Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer. Pathobiology 82(6):269–279

Klempner SJ et al (2019) FGFR2-altered gastroesophageal adenocarcinomas are an uncommon clinicopathologic entity with a distinct genomic landscape. Oncologist 24(11):1462–1468

Tokunaga R et al (2016) Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget 7(15):19748–19761

Epstein RJ, Tian LJ, Gu YF (2021.) 2b or not 2b: how opposing FGF receptor splice variants are blocking progress in precision oncology. J Oncol 2021:9955456

Yashiro M et al (2021) Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci Rep 11(1):4698

Okamura R et al (2018) Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol 2018:PO.18.00183. https://doi.org/10.1200/PO.18.00183. Epub 15 Nov 2018

Wierz M et al (2018) Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood 131(14):1617–1621

Puhr HC, Ilhan-Mutlu A (2019) New emerging targets in cancer immunotherapy: the role of LAG3. ESMO Open 4(e000482):2

Morel KL et al (2021) EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD‑1 checkpoint blockade in prostate cancer. Nat Cancer 2(4):444–456

Loeser H et al (2019) The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. OncoImmunology 8(5):e1581546

Gebauer F et al (2020) Lymphocyte activation gene‑3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. J Cancer Res Clin Oncol 146(9):2319–2327

Wagener-Ryczek S et al (2020) Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma. Cancer Immunol Immunother 69(4):523–533

Frankell AM et al (2019) The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet 51(3):506–516

Janjigian YY et al (2018) Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 8(1):49–58

Hussain M et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383(24):2345–2357